Bringing a new drug or biologic to market is a lengthy and highly regulated process that requires extensive scientific evidence, robust quality documentation, and close collaboration with regulatory authorities. To improve review efficiency without compromising safety or effectiveness, the U.S. Food and Drug Administration (FDA) introduced the FDA STAR Program, an innovative initiative designed to streamline regulatory reviews. Through Split Real-Time Application Review, the FDA can begin evaluating portions of a marketing application before receiving the complete submission, helping sponsors address questions earlier and potentially shortening the overall FDA Drug Approval Process.

Traditionally, the FDA begins reviewing a New Drug Application (NDA) or Biologics License Application (BLA) only after the complete application has been submitted. Under the FDA STAR Program, sponsors submit agreed-upon sections of the application in advance, allowing FDA review teams to evaluate critical information while the remaining components are still being finalized. This collaborative approach promotes earlier communication between sponsors and regulators, helping resolve potential issues before the formal review clock begins.

A successful FDA STAR Program submission starts with comprehensive planning and regulatory strategy. Sponsors should engage with the FDA early in the product development lifecycle to determine whether their application may be suitable for Split Real-Time Application Review. Early discussions allow both parties to establish submission timelines, define which application modules will be submitted first, and align expectations regarding review activities. Proper planning significantly improves the efficiency of the review process while reducing the likelihood of avoidable delays.

Organizations pursuing accelerated review opportunities must ensure every application component meets FDA’s rigorous scientific and regulatory standards. High-quality clinical data, complete Chemistry, Manufacturing, and Controls (CMC) documentation, validated manufacturing processes, and well-organized regulatory submissions remain essential. Although the FDA STAR Program supports earlier review activities, it does not reduce the evidence required for product approval or modify FDA’s standards for safety, effectiveness, and product quality.

One of the primary advantages of Split Real-Time Application Review is the opportunity to identify regulatory concerns much earlier than under the traditional review model. FDA reviewers can evaluate submitted sections independently and communicate questions while sponsors continue preparing the remaining application modules. Addressing deficiencies early reduces the risk of significant review delays after the final application is submitted and contributes to a more predictable FDA Drug Approval Process.

The FDA STAR Program also enhances collaboration between multidisciplinary FDA review teams. Clinical reviewers, pharmacologists, statisticians, toxicologists, manufacturing experts, and regulatory specialists can begin reviewing different sections of an application simultaneously rather than waiting for a complete submission package. This coordinated review process improves communication across disciplines, supports faster issue resolution, and enables more efficient regulatory decision-making without compromising review quality.

Maintaining submission quality remains one of the most important factors in achieving successful outcomes through the FDA STAR Program. Companies should implement strong document management practices, perform comprehensive internal quality reviews, verify data accuracy, and ensure consistency across all submission modules. Effective version control, document traceability, and regulatory quality assurance help minimize inconsistencies that could otherwise delay FDA review activities.

Sponsors should also establish cross-functional collaboration throughout product development. Regulatory affairs, clinical operations, manufacturing, quality assurance, biostatistics, medical writing, and CMC teams should work together from the earliest stages of development to prepare submission-ready documentation. Early alignment among internal stakeholders improves submission quality and allows organizations to maximize the benefits of Split Real-Time Application Review.

While the FDA STAR Program offers the potential for a more efficient review timeline, participation requires ongoing communication with FDA throughout the submission process. Sponsors should promptly respond to information requests, maintain complete supporting documentation, and implement effective change management procedures whenever new data become available. Transparent communication strengthens the review process and supports timely regulatory decisions.

As FDA continues modernizing regulatory review pathways, programs such as the FDA STAR Program demonstrate the Agency’s commitment to improving efficiency while maintaining rigorous scientific standards. Companies that understand program requirements, invest in regulatory planning, and maintain high-quality submission practices are better positioned to navigate the evolving FDA Drug Approval Process successfully.

Ultimately, Split Real-Time Application Review represents a significant advancement in regulatory science by allowing earlier evaluation of critical application components without compromising FDA’s commitment to protecting public health. Organizations that integrate strategic planning, strong quality systems, and proactive regulatory engagement into their development programs can leverage the FDA STAR Program to accelerate review timelines, improve submission quality, and bring innovative therapies to patients more efficiently while maintaining full compliance with FDA regulations.